Filing Details

Accession Number:
0001209191-23-042297
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-07-14 18:09:10
Reporting Period:
2023-07-12
Accepted Time:
2023-07-14 18:09:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802768 Royalty Pharma Plc RPRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1814876 P. Terrance Coyne C/O Royalty Pharma Plc
110 East 59Th Street
New York NY 10022
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Ordinary Shares Disposition 2023-07-12 37,500 $31.07 902,500 No 4 S Indirect By TPC RP 2021, LLC
Class A Ordinary Shares Disposition 2023-07-13 37,500 $30.93 865,000 No 4 S Indirect By TPC RP 2021, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By TPC RP 2021, LLC
No 4 S Indirect By TPC RP 2021, LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Ordinary Shares 1,500 Direct
Class A Ordinary Shares 1,450 Indirect By Spouse
Class A Ordinary Shares 23,270 Indirect By IRA
Class A Ordinary Shares 24,170 Indirect By Spouse's IRA
Footnotes
  1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $31.43 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.77 to $31.44 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.